Table 1.
Characteristics of patient cohort
| Characteristic | Number | Percentage |
|---|---|---|
| Age, y | ||
| Age range | 16-70 | |
| Median age | 49 | |
| Sex | ||
| Male | 58 | 51 |
| Female | 55 | 49 |
| Cytogenetic risk stratification | ||
| Favorable risk | 5 | 4 |
| Intermediate risk | 85 | 75 |
| Adverse risk | 22 | 20 |
| Unknown | 1 | 1 |
| Disease status at transplant | ||
| CR1 | 78 | 69 |
| CR2 | 27 | 24 |
| Not in CR | 8 | 7 |
| Relapse posttransplant | 49 | 43 |
| Transplant conditioning | ||
| Reduced intensity | 75 | 66 |
| Myeloablative | 38 | 34 |
| Conditioning regimen | ||
| Flu/Mel/Campath | 58 | 51 |
| Cy/TBI | 29 | 26 |
| Flu/Mel | 9 | 8 |
| Flu/Cy/TBI | 5 | 4 |
| Bu/Cy | 5 | 4 |
| FLAMSA/TBI/ATG | 3 | 3 |
| FLAMSA/Bu/ATG | 1 | 1 |
| TBI/Flu/Cy/ATG | 1 | 1 |
| Cy/TBI/Campath | 1 | 1 |
| Bu/Flu/Thio/ATG | 1 | 1 |
| Donor source | ||
| Sibling | 49 | 43 |
| Unrelated | 61 | 54 |
| Cord | 3 | 3 |
| CMV recipient/donor | ||
| Negative/Negative | 44 | 39 |
| Positive/Positive | 33 | 29 |
| Positive/Negative | 25 | 22 |
| Negative/Positive | 11 | 10 |
| Equivocal/Negative | 1 | 1 |
| Status at last contact | ||
| Alive | 61 | 54 |
| Dead | 52 | 46 |
ATG, antithymocyte globulin; Bu, busulfan; CMV, cytomegalovirus; Cy, cyclophosphamide; FLAMSA, fludarabine, cytarabine, amsacrine, cyclosphosphamide; Flu, fludarabine; Mel, melphalan; Thio, thiotepa; TBI, total body irradiation.